Wolverine Trading’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-266,200
| Closed | -$9.77M | – | 6181 |
|
|
2025
Q2 | $9.77M | Buy |
266,200
+46,600
| +21% | +$1.73M | 0.01% | 723 |
|
|
2025
Q1 | $8.75M | Sell |
219,600
-2,700
| -1% | -$90.8K | 0.01% | 690 |
|
|
2024
Q4 | $6.99M | Buy |
222,300
+55,000
| +33% | +$1.58M | 0.01% | 989 |
|
|
2024
Q3 | $3.99M | Buy |
167,300
+43,300
| +35% | +$946K | ﹤0.01% | 1197 |
|
|
2024
Q2 | $2.21M | Buy |
124,000
+13,700
| +12% | +$219K | ﹤0.01% | 1539 |
|
|
2024
Q1 | $1.68M | Sell |
110,300
-77,100
| -41% | -$1.23M | ﹤0.01% | 1746 |
|
|
2023
Q4 | $3.2M | Buy |
187,400
+54,400
| +41% | +$632K | ﹤0.01% | 1360 |
|
|
2023
Q3 | $1.11M | Sell |
133,000
-62,400
| -32% | -$870K | ﹤0.01% | 2043 |
|
|
2023
Q2 | $4.71M | Buy |
195,400
+109,400
| +127% | +$2.83M | 0.01% | 944 |
|
|
2023
Q1 | $1.26M | Buy |
+86,000
| New | +$1.31M | ﹤0.01% | 1715 |
|
|
2022
Q4 | – | Sell |
-44,800
| Closed | -$268K | – | 5026 |
|
|
2022
Q3 | $268K | Buy |
44,800
+6,900
| +18% | +$45.3K | ﹤0.01% | 3273 |
|
|
2022
Q2 | $164K | Sell |
37,900
-8,600
| -18% | -$53.7K | ﹤0.01% | 3643 |
|
|
2022
Q1 | $457K | Sell |
46,500
-24,900
| -35% | -$288K | ﹤0.01% | 3351 |
|
|
2021
Q4 | $1.38M | Buy |
71,400
+15,900
| +29% | +$413K | ﹤0.01% | 2264 |
|
|
2021
Q3 | $1.86M | Buy |
55,500
+15,000
| +37% | +$464K | ﹤0.01% | 2235 |
|
|
2021
Q2 | $1.52M | Buy |
40,500
+7,000
| +21% | +$275K | ﹤0.01% | 2270 |
|
|
2021
Q1 | $1.52M | Sell |
33,500
-56,200
| -63% | -$2.7M | ﹤0.01% | 2242 |
|
|
2020
Q4 | $4.74M | Buy |
89,700
+12,600
| +16% | +$426K | 0.01% | 1091 |
|
|
2020
Q3 | $2.02M | Sell |
77,100
-23,300
| -23% | -$536K | ﹤0.01% | 1475 |
|
|
2020
Q2 | $1.86M | Sell |
100,400
-92,900
| -48% | -$1.5M | 0.01% | 1471 |
|
|
2020
Q1 | $2M | Sell |
193,300
-1,800
| -0.9% | -$22.7K | 0.01% | 1337 |
|
|
2019
Q4 | $2.12M | Buy |
195,100
+76,800
| +65% | +$584K | 0.01% | 1792 |
|
|
2019
Q3 | $668K | Buy |
118,300
+38,500
| +48% | +$268K | ﹤0.01% | 2325 |
|
|
2019
Q2 | $690K | Buy |
79,800
+3,300
| +4% | +$24.9K | ﹤0.01% | 2386 |
|
|
2019
Q1 | $615K | Sell |
76,500
-109,700
| -59% | -$593K | ﹤0.01% | 2543 |
|
|
2018
Q4 | $741K | Sell |
186,200
-28,900
| -13% | -$144K | ﹤0.01% | 2256 |
|
|
2018
Q3 | $1.21M | Buy |
215,100
+4,000
| +2% | +$45.7K | ﹤0.01% | 2146 |
|
|
2018
Q2 | $3M | Hold |
211,100
| – | – | 0.01% | 1251 |
|
|
2018
Q1 | $3M | Buy |
+211,100
| New | +$2.7M | 0.01% | 1251 |
|
|
2017
Q4 | – | Sell |
-118,000
| Closed | -$1.4M | – | 5475 |
|
|
2017
Q3 | $1.4M | Buy |
118,000
+51,100
| +76% | +$582K | 0.01% | 1603 |
|
|
2017
Q2 | $709K | Sell |
66,900
-18,300
| -21% | -$205K | ﹤0.01% | 2079 |
|
|
2017
Q1 | $976K | Buy |
+85,200
| New | +$612K | 0.01% | 1739 |
|
Other funds holding TGTX
SCM
HRCM
Wolverine Trading's TGTX Position: Q2 2025 in Review
Wolverine Trading sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 6,120 shares — an estimated $228K sold.
Wolverine Trading first reported a position in TGTX in Q2 2016 and held it in 27 quarters. The position peaked at $4.56M in Q4 2020. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.
- Wolverine Trading reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
- Wolverine Trading sold 6,120 TG Therapeutics shares in Q2 2025, an estimated $228K.
- Wolverine Trading first reported a position in TG Therapeutics in Q2 2016 and held it in 27 quarters.
- Wolverine Trading's TG Therapeutics position peaked at $4.56M in Q4 2020.
- 356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.
Based on Wolverine Trading's 13F filing for Q2 2025, filed 18 Aug 2025.